Pediatr Allergy Respir Dis.  2004 Mar;14(1):80-86.

Changes in Peripheral Blood T Cells after Treatment of Cyclosporine in Children with Severe Atopic Dermatitis

Affiliations
  • 1Department of Pediatrics, College of Medicine, Ulsan University, Korea. sjhong@amc.seoul.kr
  • 2Department of Pediatrics, College of Medicine, Sungkyunkwan University, Korea.
  • 3Asan Institute for Life Science, Seoul, Korea.

Abstract

BACKGROUND
Skin-homing T cells expressing cutaneous lymphocyte antigen (CLA) are known to be important in the pathogenesis of atopic dermatitis (AD). Cyclosporine is known as an effective treatment for severe atopic dermatitis, which controls the cytokine production from T cells and regulates the activation of T cells. There have been no reports about the changes of circulating CLA+ T cells after the treatment of cyclosporine in AD. The aim of this study was to evaluate the clinical outcome and the changes of CLA+ T cells after treatment of cyclosporine in childhood AD. METHODS: Ten children with severe AD were treated with cyclosporine (5 mg/kg/day) for six weeks. Clinical outcome was monitored by the SCORAD index. We assayed the peripheral blood T lymphocyte subpopulation including CLA+ T cells with flow cytometry. RESULTS: The SCORAD index decreased significantly after treatment (P< 0.05). CD4+CLA+ T cells and CD3+CLA+ T cells were significantly decreased after the treatment of cyclosporine. (P< 0.05) But CD3+ T cells, CD4+ T cells and CD8+ T cells were not changed. CONCLUSION: Cyclosporine is effective to control severe AD in children and decreases CD4+CLA+ T cells, which may be important in the pathogenesis of AD.

Keyword

Atopic dermatitis; Cyclosporine; Cutaneous lymphocyte antigen

MeSH Terms

Child*
Cyclosporine*
Dermatitis, Atopic*
Flow Cytometry
Humans
Lymphocyte Subsets
Lymphocytes
T-Lymphocytes*
Cyclosporine
Full Text Links
  • PARD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr